Artículos de revistas sobre el tema "Inhibitor of HDAC6"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Inhibitor of HDAC6".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Stubbs, Matthew C., Won-Il Kim, Tina Davis, Jun Qi, James Bradner, Andrew L. Kung y Scott A. Armstrong. "Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All". Blood 116, n.º 21 (19 de noviembre de 2010): 2900. http://dx.doi.org/10.1182/blood.v116.21.2900.2900.
Texto completoKhan, Nagma, Michael Jeffers, Sampath Kumar, Craig Hackett, Ferenc Boldog, Nicholai Khramtsov, Xiaozhong Qian et al. "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors". Biochemical Journal 409, n.º 2 (21 de diciembre de 2007): 581–89. http://dx.doi.org/10.1042/bj20070779.
Texto completoCao, Jiangying, Wei Zhao, Chunlong Zhao, Qian Liu, Shunda Li, Guozhen Zhang, C. James Chou y Yingjie Zhang. "Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC". Molecules 25, n.º 21 (28 de octubre de 2020): 4991. http://dx.doi.org/10.3390/molecules25214991.
Texto completoSkov, Vibe, Thomas Stauffer Larsen, Mads Thomassen, Caroline Riley, Morten Krogh Jensen, Ole Weis Bjerrum, Torben A. Kruse y Hans Carl Hasselbalch. "Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms". Blood 116, n.º 21 (19 de noviembre de 2010): 4119. http://dx.doi.org/10.1182/blood.v116.21.4119.4119.
Texto completoBui, Hue Thi Buu, Phuong Hong Nguyen, Quan Minh Pham, Hoa Phuong Tran, De Quang Tran, Hosun Jung, Quang Vinh Hong et al. "Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety". Molecules 27, n.º 7 (28 de marzo de 2022): 2204. http://dx.doi.org/10.3390/molecules27072204.
Texto completoVarricchio, Lilian, Carmela Dell'Aversana, Angela Nebbioso, Giovanni Migliaccio, Lucia Altucci, James J. Bieker y Anna Rita F. Migliaccio. "Identification of a New Functional HDAC Complex Composed by HDAC5, GATA1 and EKLF in Human Erythroid Cells". Blood 120, n.º 21 (16 de noviembre de 2012): 979. http://dx.doi.org/10.1182/blood.v120.21.979.979.
Texto completoKraft, Fabian B., Maria Hanl, Felix Feller, Linda Schäker-Hübner y Finn K. Hansen. "Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy". Pharmaceuticals 16, n.º 3 (25 de febrero de 2023): 356. http://dx.doi.org/10.3390/ph16030356.
Texto completoPerez-Salvia, Montserrat, Aldaba Eneko, Vara Yosu, Fabre Myriam, Ferrer Cristina, Masdeu Carme, Zubia Aizpea et al. "Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia". Blood 132, Supplement 1 (29 de noviembre de 2018): 5383. http://dx.doi.org/10.1182/blood-2018-99-111578.
Texto completoLodish, Harvey F. y Peng Ji. "Enucleation." Blood 114, n.º 22 (20 de noviembre de 2009): SCI—18—SCI—18. http://dx.doi.org/10.1182/blood.v114.22.sci-18.sci-18.
Texto completoHancock, Wayne W. "Epigenetic Regulation of Regulatory T-Cells: Impact on Autoimmunity and Graft Rejection". Blood 116, n.º 21 (19 de noviembre de 2010): SCI—23—SCI—23. http://dx.doi.org/10.1182/blood.v116.21.sci-23.sci-23.
Texto completoMarlow, Laura A., Ilah Bok, Robert C. Smallridge y John A. Copland. "RhoB upregulation leads to either apoptosis or cytostasis through differential target selection". Endocrine-Related Cancer 22, n.º 5 (23 de julio de 2015): 777–92. http://dx.doi.org/10.1530/erc-14-0302.
Texto completoAriffin, Juliana K., Kaustav das Gupta, Ronan Kapetanovic, Abishek Iyer, Robert C. Reid, David P. Fairlie y Matthew J. Sweet. "Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages". Antimicrobial Agents and Chemotherapy 60, n.º 3 (28 de diciembre de 2015): 1521–29. http://dx.doi.org/10.1128/aac.01876-15.
Texto completoHackanson, Bjorn W., Leander Rimmele, Manfred Jung y Michael Lübbert. "Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines." Blood 114, n.º 22 (20 de noviembre de 2009): 4808. http://dx.doi.org/10.1182/blood.v114.22.4808.4808.
Texto completoLaschanzky, Richard S., Lisa E. Humphrey, Jihyun Ma, Lynette M. Smith, Thomas J. Enke, Surendra K. Shukla, Aneesha Dasgupta et al. "Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy". Cancers 11, n.º 9 (7 de septiembre de 2019): 1327. http://dx.doi.org/10.3390/cancers11091327.
Texto completoClauß, Oliver, Linda Schäker-Hübner, Barbara Wenzel, Magali Toussaint, Winnie Deuther-Conrad, Daniel Gündel, Rodrigo Teodoro et al. "Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain". Pharmaceuticals 15, n.º 3 (8 de marzo de 2022): 324. http://dx.doi.org/10.3390/ph15030324.
Texto completoKnox, Tessa, Maritza Lienlaf, Patricio Perez-Villarroel, Calvin Lee, Eva Sahakian, John J. Powers, Fengdong Cheng et al. "Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition". Blood 124, n.º 21 (6 de diciembre de 2014): 5423. http://dx.doi.org/10.1182/blood.v124.21.5423.5423.
Texto completoMensah, Afua Adjeiwaa, Sergio Valente, Milos Matkovic, Giulio Sartori, Chiara Falzarano, Chiara Tarantelli, Luciano Cascione et al. "Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 3279. http://dx.doi.org/10.1158/1538-7445.am2022-3279.
Texto completoFreese, Kim, Tatjana Seitz, Peter Dietrich, Serene M. L. Lee, Wolfgang E. Thasler, Anja Bosserhoff y Claus Hellerbrand. "Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro". Cancers 11, n.º 10 (18 de octubre de 2019): 1587. http://dx.doi.org/10.3390/cancers11101587.
Texto completoCheng, Fengdong, Bing Xia, Eva Sahakian, Tint Lwin, Hongwei Wang, Limin Xing, Bijal D. Shah et al. "Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)". Blood 124, n.º 21 (6 de diciembre de 2014): 5397. http://dx.doi.org/10.1182/blood.v124.21.5397.5397.
Texto completoBaumann, Philipp, Carmen Junghanns, Strobl Stefan, Fuat Oduncu y Ralf Schmidmaier. "The Novel Pan-HDAC Inhibitor CR2408 Inhibits Multiple Myeloma Cell Growth and Proliferation". Blood 118, n.º 21 (18 de noviembre de 2011): 5133. http://dx.doi.org/10.1182/blood.v118.21.5133.5133.
Texto completoVerbeek, Tamara C. A. I., Susan Arentsen-Peters, Patricia Garrido Castro, Sandra Pinhancos, Kirsten Vrenken, Aida Varela-Moreira, M. Emmy Dolman, Bianca Koopmans, Rob Pieters y Ronald W. Stam. "Selective Inhibition of Class II HDAC Isoforms 4 and 5 Provides a Promising Therapeutic Intervention for MLL-Rearranged Acute Lymphoblastic Leukemia in Infants". Blood 138, Supplement 1 (5 de noviembre de 2021): 2206. http://dx.doi.org/10.1182/blood-2021-147164.
Texto completoZhang, Bingbing, Zhu-Wei Ruan, Dongdong Luo, Yueyue Zhu, Tingbo Ding, Qiang Sui y Xinsheng Lei. "Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole". Marine Drugs 18, n.º 7 (30 de junio de 2020): 344. http://dx.doi.org/10.3390/md18070344.
Texto completoJoshi, Atul D., Nektarios Barabutis, Charalampos Birmpas, Christiana Dimitropoulou, Gagan Thangjam, Mary Cherian-Shaw, John Dennison y John D. Catravas. "Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function". American Journal of Physiology-Lung Cellular and Molecular Physiology 309, n.º 12 (15 de diciembre de 2015): L1410—L1419. http://dx.doi.org/10.1152/ajplung.00180.2015.
Texto completoKitadate, Akihiro, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue y Hiroyuki Tagawa. "Histone Deacetylase Inhibitors Downregulate CCR4 Expression and Decrease Mogamulizumab Efficacy in CCR4-Positive Mature T-Cell Lymphomas". Blood 130, Suppl_1 (7 de diciembre de 2017): 720. http://dx.doi.org/10.1182/blood.v130.suppl_1.720.720.
Texto completoS, Dhanalakshmi, Sridharan Rajagopal, Naveen Sadhu, Chandru G, Amir Siddiqui, Saif Wahid, Basava Prabhu et al. "Novel Dual Inhibitor of LSD1-HDAC6/8 for Treatment of Cancer". Blood 136, Supplement 1 (5 de noviembre de 2020): 29. http://dx.doi.org/10.1182/blood-2020-142685.
Texto completoAngiolilli, Chiara, Pawel A. Kabala, Aleksander M. Grabiec, Iris M. Van Baarsen, Bradley S. Ferguson, Samuel García, Beatriz Malvar Fernandez et al. "Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes". Annals of the Rheumatic Diseases 76, n.º 1 (25 de julio de 2016): 277–85. http://dx.doi.org/10.1136/annrheumdis-2015-209064.
Texto completoPorter, Nicholas J., Adaickapillai Mahendran, Ronald Breslow y David W. Christianson. "Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors". Proceedings of the National Academy of Sciences 114, n.º 51 (4 de diciembre de 2017): 13459–64. http://dx.doi.org/10.1073/pnas.1718823114.
Texto completoGrégoire, Serge, Lin Xiao, Jianyun Nie, Xiaohong Zhang, Minghong Xu, Jiarong Li, Jiemin Wong, Edward Seto y Xiang-Jiao Yang. "Histone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2". Molecular and Cellular Biology 27, n.º 4 (11 de diciembre de 2006): 1280–95. http://dx.doi.org/10.1128/mcb.00882-06.
Texto completoImai, Yoichi, Mitsuhito Hirano, Masayuki Kobayashi, Muneyoshi Futami y Arinobu Tojo. "HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action". Cancers 11, n.º 4 (4 de abril de 2019): 475. http://dx.doi.org/10.3390/cancers11040475.
Texto completoBerger, Allison J., Bret Bannerman, Steven N. Quayle, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, David Tamang, Min Yang y Simon S. Jones. "Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models". Blood 122, n.º 21 (15 de noviembre de 2013): 4437. http://dx.doi.org/10.1182/blood.v122.21.4437.4437.
Texto completoRen, Jingjing, Xiaofeng Liao, Miranda Vieson, Kristin Eden, Miao Chen, Reilly Scott, Jillian Kazmierczak, Xin M. Luo y Christopher M. Reilly. "Selective HDAC6 inhibitor decreases lupus in mice". Journal of Immunology 198, n.º 1_Supplement (1 de mayo de 2017): 224.19. http://dx.doi.org/10.4049/jimmunol.198.supp.224.19.
Texto completoSharma, Chiranjeev, Yong Jin Oh, Byoungduck Park, Sooyeun Lee, Chul-Ho Jeong, Sangkil Lee, Ji Hae Seo y Young Ho Seo. "Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction". International Journal of Molecular Sciences 20, n.º 24 (9 de diciembre de 2019): 6213. http://dx.doi.org/10.3390/ijms20246213.
Texto completoLagosz, K. B., A. Bysiek, J. M. Macina, G. P. Bereta, M. Kantorowicz, W. Lipska, M. Sochalska et al. "HDAC3 Regulates Gingival Fibroblast Inflammatory Responses in Periodontitis". Journal of Dental Research 99, n.º 1 (6 de noviembre de 2019): 98–106. http://dx.doi.org/10.1177/0022034519885088.
Texto completoLaino, Andressa Sodre, David M. Woods, Fengdong Cheng, Hongwei Wang y Eduardo M. Sotomayor. "Histone Deacetylase 6 (HDAC6) Influences T-Cell Activation and Survival: Implications For Cancer Immunotherapy". Blood 122, n.º 21 (15 de noviembre de 2013): 1050. http://dx.doi.org/10.1182/blood.v122.21.1050.1050.
Texto completoHolt, Jason A., Edward P. Garvey, J. David Becherer, William J. Hoekstra, Robert J. Schotzinger y Christopher M. Yates. "SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo". Blood 132, Supplement 1 (29 de noviembre de 2018): 3215. http://dx.doi.org/10.1182/blood-2018-99-113066.
Texto completoShen, Xiaokun y Zeng Li. "Abstract P3-05-05: Preclinical evaluation of novel HDAC6 selective inhibitors N008 with potent in vitroandin vivoprofiles in non-solid tumor and solid tumors". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P3–05–05—P3–05–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-05-05.
Texto completoBulut, Ipek, Adam Lee, Buse Cevatemre, Dusan Ruzic, Roman Belle, Akane Kawamura, Sheraz Gul, Katarina Nikolic, A. Ganesan y Ceyda Acilan. "Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells". Cancers 14, n.º 23 (6 de diciembre de 2022): 6014. http://dx.doi.org/10.3390/cancers14236014.
Texto completoHanemann, Clemens Oliver y Juri Na. "EXTH-90. HDAC INHIBITOR, CAY10603, IS A POTENT RADIOSENSITIZER IN MENINGIOMAS". Neuro-Oncology 24, Supplement_7 (1 de noviembre de 2022): vii230. http://dx.doi.org/10.1093/neuonc/noac209.888.
Texto completoHarada, Takeshi, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi et al. "Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma". Blood 134, Supplement_1 (13 de noviembre de 2019): 3111. http://dx.doi.org/10.1182/blood-2019-127679.
Texto completoKim, Ji Yoon, Seung Yoon Han, Jung Yoo, Go Woon Kim, Yu Hyun Jeon, Sang Wu Lee, Jongsun Park y So Hee Kwon. "HDAC8-Selective Inhibition by PCI-34051 Enhances the Anticancer Effects of ACY-241 in Ovarian Cancer Cells". International Journal of Molecular Sciences 23, n.º 15 (3 de agosto de 2022): 8645. http://dx.doi.org/10.3390/ijms23158645.
Texto completoSixto-López, Yudibeth, Martha Cecilia Rosales-Hernández, Arturo Contis-Montes de Oca, Leticia Guadalupe Fragoso-Morales, Jessica Elena Mendieta-Wejebe, Ana María Correa-Basurto, Edgar Abarca-Rojano y José Correa-Basurto. "N-(2′-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Inhibits HDAC1 and Increases the Translocation of HMGB1 Levels in Human Cervical Cancer Cells". International Journal of Molecular Sciences 21, n.º 16 (16 de agosto de 2020): 5873. http://dx.doi.org/10.3390/ijms21165873.
Texto completoHess, Lena, Verena Moos, Arnel A. Lauber, Wolfgang Reiter, Michael Schuster, Natascha Hartl, Daniel Lackner et al. "A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation". PLOS Genetics 18, n.º 8 (22 de agosto de 2022): e1010376. http://dx.doi.org/10.1371/journal.pgen.1010376.
Texto completoMasselli, Elena, Lilian Varricchio, Barbara Ghinassi, Carolyn Whitsett, Patricia A. Shi y Anna Rita F. Migliaccio. "Class IIa HDAC Inhibitors Reduce HDAC1 Activity by off-Target Effects Which Reduce GATA1 Expression In Human Erythroblasts Expanded Ex-Vivo". Blood 116, n.º 21 (19 de noviembre de 2010): 4780. http://dx.doi.org/10.1182/blood.v116.21.4780.4780.
Texto completoKikuchi, Jiro, Taeko Wada, Rumi Shimizu, Tohru Izumi, Miyuki Akutsu, Kanae Mitsunaga, Kaoru Noborio-Hatano et al. "Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma". Blood 116, n.º 3 (22 de julio de 2010): 406–17. http://dx.doi.org/10.1182/blood-2009-07-235663.
Texto completoLeucker, Thorsten M., Yohei Nomura, Jae Hyung Kim, Anil Bhatta, Victor Wang, Andrea Wecker, Sandeep Jandu et al. "Cystathionine γ-lyase protects vascular endothelium: a role for inhibition of histone deacetylase 6". American Journal of Physiology-Heart and Circulatory Physiology 312, n.º 4 (1 de abril de 2017): H711—H720. http://dx.doi.org/10.1152/ajpheart.00724.2016.
Texto completoOsko, Jeremy D. y David W. Christianson. "Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6". Acta Crystallographica Section F Structural Biology Communications 76, n.º 9 (19 de agosto de 2020): 428–37. http://dx.doi.org/10.1107/s2053230x20010250.
Texto completoCao, Biyin, Mingyun Shen, Depei Wu, Jianhong Du, Jingyu Zhu, Suning Chen, Aining Sun et al. "The Proteasomal Inhibitor Clioquinol Induces Apoptosis in Leukemia and Myeloma Cells by Inhibiting Histone Deacetylase Activity." Blood 120, n.º 21 (16 de noviembre de 2012): 2449. http://dx.doi.org/10.1182/blood.v120.21.2449.2449.
Texto completoIaconelli, Jonathan, Lucius Xuan y Rakesh Karmacharya. "HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons". International Journal of Molecular Sciences 20, n.º 7 (31 de marzo de 2019): 1605. http://dx.doi.org/10.3390/ijms20071605.
Texto completoQuayle, Steven N., David Tamang, Min Yang y Simon S. Jones. "Inhibition Of HDAC6 In Combination With Targeted Agents Results In Broad Synergistic Decreases In Viability In Non-Hodgkin’s Lymphoma (NHL) Cells". Blood 122, n.º 21 (15 de noviembre de 2013): 3071. http://dx.doi.org/10.1182/blood.v122.21.3071.3071.
Texto completoWen, Zhi-Hong, Jhy-Shrian Huang, Yen-You Lin, Zhi-Kang Yao, Yu-Cheng Lai, Wu-Fu Chen, Hsin-Tzu Liu et al. "Chondroprotective Effects of a Histone Deacetylase Inhibitor, Panobinostat, on Pain Behavior and Cartilage Degradation in Anterior Cruciate Ligament Transection-Induced Experimental Osteoarthritic Rats". International Journal of Molecular Sciences 22, n.º 14 (7 de julio de 2021): 7290. http://dx.doi.org/10.3390/ijms22147290.
Texto completo